Search Results for "finasteride"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for finasteride. Results 1 to 3 of 3 total matches.
See also: Propecia, Proscar

A Fixed-Dose Combination of Finasteride and Tadalafil (Entadfi) for BPH (online only)

   
The Medical Letter on Drugs and Therapeutics • Sep 05, 2022  (Issue 1658)
A Fixed-Dose Combination of Finasteride and Tadalafil (Entadfi) for BPH (online only) ...
The FDA has approved Entadfi (Veru), a fixed-dose combination of the 5α-reductase inhibitor finasteride and the phosphodiesterase type 5 (PDE5) inhibitor tadalafil, for initial treatment of benign prostatic hyperplasia (BPH) in men with an enlarged prostate; use of the drug is limited to 26 weeks. Entadfi is the first 5α-reductase inhibitor/PDE5 inhibitor combination to become available in the US. Finasteride (Proscar, and generics) and tadalafil (Cialis, and generics) are also available separately.
Med Lett Drugs Ther. 2022 Sep 5;64(1658):e1-2 |  Show IntroductionHide Introduction

Drugs for Benign Prostatic Hyperplasia

   
The Medical Letter on Drugs and Therapeutics • May 02, 2022  (Issue 1649)
finasteride and dutasteride can reduce prostatic volume and decrease urinary retention and the need ...
About 60% of men ≥60 years old have clinically relevant prostatic enlargement due to benign prostatic hyperplasia (BPH). The goals of treatment are to decrease lower urinary tract symptoms and to prevent disease progression and complications such as acute urinary retention. The American Urologic Association's guidelines for treatment of BPH were recently updated.
Med Lett Drugs Ther. 2022 May 2;64(1649):65-9 |  Show IntroductionHide Introduction

Phosphodiesterase-5 Inhibitors for Alzheimer's Disease?

   
The Medical Letter on Drugs and Therapeutics • Oct 31, 2022  (Issue 1662)
arterial hypertension. Tadalafil is also approved alone (Cialis) and in combination with finasteride ...
A reader asked us to review use of the phosphodiesterase-5 (PDE5) inhibitor sildenafil for treatment of Alzheimer's disease (AD).
Med Lett Drugs Ther. 2022 Oct 31;64(1662):174-5 |  Show IntroductionHide Introduction